AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years

• Status: Completed
• Trial end date: 2009-11-01
• Target enrollment: 0
• Participant gender: All

Summary

AML2003 is a prospective randomized trial, to investigate the value of early allogeneic stem cell transplantation in aplasia after induction therapy for high risk patients with acute myeloid leukemia.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Technische Universität Dresden
• Treatments: Amsacrine; Cytarabine; Mitoxantrone

Criteria

Inclusion Criteria:

• de novo or secondary acute myeloid leukemia FAB-subtypes M0-M2 and M4-M7

• de novo or secondary myelodysplastic syndrome WHO-type RAEB-2

• age 16 to 60 years

• written informed consent

Exclusion Criteria:

• severe comorbidities

• severe, uncontrolled complications of the leukemia

• prior therapy for AML/MDS

• other simultaneous hematological malignancies

• HIV-Infection

• known allergies against study medication

• pregnancy

• missing written informed consent